The global coccidioidomycosis drug market is expected to grow at a significant CAGR during the forecast period (2022-2028). The fungal infection causes coccidioidomycosis, popularly known as valley fever. The fungus that causes coccidioidomycosis is called coccidioides, and it lives in soil in Mexico, the southern US, Central America, and South America. Valley fever is spread by inhaling fungus spores that are present in the air. Valley fever is characterized by fatigue, headaches, night sweats, muscle aches, and shortness of breath, among other symptoms. It is a short-term disease that has been documented to last a few days or weeks, however, some people who are affected develop symptoms that persist longer and the infection progresses to a severe form. According to the CDC, between 5 to 10% of infected people develop serious infections, necessitating effective treatment in order to live a disease-free life. Valley fever is diagnosed using a simple blood test that looks for Coccidioides antibodies or antigens, as well as a skin test to see if a person's immune response to the Coccidioides infection is working properly. Antifungal medications, such as fluconazole, are commonly used to treat coccidioidomycosis.

According to the Centers for Disease Control and Prevention (CDC), there were 18,407 cases of Valley fever reported in 2019. The majority of these occurrences occurred in the residents of Arizona and California. Valley fever is more common among persons in their 60s and older. According to data from the National Multiple Cause of Death Registry, there were roughly 200 coccidioidomycosis-related deaths per year in the US between 1999 and 2019.

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, in December 2021, Sun Pharmaceutical Industries announced that the US FDA has given final approval to one of its wholly-owned subsidiaries' abbreviated new drug application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial single-dose vial. The generic product approval is based on the reference product AmBisome Liposome for Injection, 50 mg/vial. Antifungal medicine amphotericin B is used to treat serious fungal infections including leishmaniasis, mucormycosis, aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, and cryptococcosis.  

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027

Segment Covered- 

• By Disease Type 
• By End-User 

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Johnson & Johnson Services, Inc., Pfizer Inc., and Sun Pharmaceutical Industries Ltd., among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Coccidioidomycosis Drug Market Report by Segment

By Disease Type 

• Acute Coccidioidomycosis
• Chronic Coccidioidomycosis
• Disseminated Coccidioidomycosis.

By End-User 

• Specialty clinics
• Hospitals
• Homecare
• Others

Global Coccidioidomycosis Drug Market Report by Region

• North America       
• US
• Canada
• Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• The Middle East and Africa